AJTM Advertising Policy


1. All advertisements are subject to approval of the American Journal of Translational Medicine, which reserves the right to reject or cancel any ad at any time.


2. All advertisements are accepted and published by Publisher on the warranty of the agency and advertiser that both are authorized to publish the entire contents and subject matter of the advertisement.


3. In consideration of publication of an advertisement, the advertiser and the agency, jointly and severally, agree to indemnify and hold harmless Publisher, its officers, agents and employees against expenses (including legal fees) and losses resulting from the publication of the contents of the advertisement, including, without limitation, claims or suits for libel, violation of privacy, copyright infringement or plagiarism.


4. Publisher will not be liable for any failure to publish any advertisement accepted by Publisher; however, Publisher shall use its reasonable efforts to place such advertisement in subsequent available space.


5. All advertisements must clearly and prominently identify the advertiser by trademark or signature.


6. For advertorial guidelines contact your Sales Director.


7. Any references to Publisher or its products or services in advertisements, promotional material or merchandising by the advertiser or agency is subject to Publisher’s written approval for such use.


8. All advertising contract position clauses are treated as requests. Publisher cannot guarantee fixed positioning.


9. Publisher is not responsible for incidental or consequential damage for errors in displaying or printing an ad.


10. Publisher may change the terms set forth herein at any time, provided that no such change applies to ads whose closing date precedes the announcement of the change.


11. Publisher will not be bound by any condition, printed or otherwise, appearing on any insertion order or copy instructions when such conditions conflict with the conditions set forth in this rate card.


12. In the event of nonpayment, Publisher reserves the right to hold advertiser and/or its advertising agency jointly and severally liable for such monies as are past due and payable to Publisher.


13. Proprietary names of pharmaceutical products must be accompanied by the chemical, generic or official name; the quantity of all active substances must be stated along with the recommended dosage. New ad copy and creative for pharmaceutical products should be sent to the advertising department. Please allow two weeks for clearance.


14. All advertisements must be clearly germane to the medicine, including medical research, disease diagnosis, and treatment etc.


15. Advertiser represents and warrants that all advertisements and pharmaceutical products they advertise are compliant with all applicable laws, rules, and regulations in the country where the advertisement will be seen. Advertisements for pharmaceutical products (including NDA products) that are subject to US Food and Drug Administration (FDA) oversight must comply with FDA regulations regarding advertising and promotion.


16. Any use of Publisher’s trademarks (including the American Journal of Translational Medicine and its logo design, AJTM, or copyrighted material for links to and from a Publisher website must be approved in advance by Publisher. Publisher does not endorse or support any product or organization linked to its website, nor is Publisher responsible for the content of any website promoted in any advertisement appearing at a Publisher website.


17. All advertisements at served on article pages are served on a random basis, in rotation with Hawaii Gangze advertising and recruitment advertising. The random placement algorithm does not permit any commercial ad to be targeted to any specific article or any specific user or groups of users.  Advertisers have no advance knowledge of and no control over ad placement.  Neither the Publisher nor its publications endorse any company, product, or service.

Recruitment ads must be nondiscriminatory and comply with all applicable laws and regulations. Ads that discriminate against applicants based on sex, age, race, religion, marital status or physical handicap will not be accepted. Non-US recruitment advertisers are required to confirm in writing that they are equal opportunity employers.




Advertiser may cancel the entire Insertion Order, or any portion thereof, as follows:


Run-Of-Site Banner Programs:

On written notice to Publisher given 21 or more days before the start date. With cancellations inside 21 days of the start date, advertiser will be responsible for 50% of the Insertion Order amount that was reserved for delivery.


On written notice to Publisher given 30 or more days before the start date. With cancellations inside 30 days of the start date, advertiser will be responsible for 50% of the IO amount that was reserved for delivery.

Copyright(C)2017 American Journal of Translational Medicine